CSLLY News and Press, CSL Ltd ADR From 10/06/22

CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine PR Newswire CSL Seqirus will manufacture and clinically assess a cell-based, adjuvanted pre-pandemic influenza vaccine candidate to support the U.S. ...

CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates PR Newswire Data published in Molecular Therapy – Methods and Clinical Development confirm the potential preclinical benefit of the sa-mRNA technol...

New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems PR Newswire SUMMIT, N.J. , Sept. 26, 2022 /PRNewswire/ -- CSL Seqirus, a b...

New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates PR Newswire SUMMIT, N.J. , Sept. 26, 2022 /PRNewswire/ -- CSL Seqirus, a business of CSL Limited (ASX:CSL), today annou...

CSL presents new research and development center in Marburg, Germany PR Newswire The new facility, once fully open later this calendar year, will be CSL's largest R&D site under one roof, with more than 500 team members working in a state-of-the-art facility offeri...

CSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XI PR Newswire SUMMIT, N.J. , Sept. 13, 2022 /PRNewswire/ -- CSL Seqirus, a part of CSL Limited (ASX:CSL), today announced new data will be present...

CSL Plasma Provides Free Flu Vaccines to U.S. Plasma Donors PR Newswire Vouchers enable donors at 300+ U.S. CSL Plasma donation centers to receive free flu shots at Walgreens pharmacy locations nationally BOCA RATON, Fla. , Sept. 8, 2022 /PRNewswi...

The superior reactogenicity profile of Novavax's Nuvaxovid vaccine could make it the preferred choice amongst some in an endemic COVID environment. The company's other promising vaccine, NanoFlu, is being overlooked due to the market's focus on COVID. The recent decline in the NVA...

Both the FY 2022 top line and bottom line for CSL didn't meet the market's expectations, with the weakness associated with the core Behring business segment being a key factor. The FY 2023 outlook for CSL is better than management guidance suggested, taking into account one-off items....

A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan will be a first-in-class treatment to address the significant unmet medical need in IgA nephropathy (IgAN) in Europe SAN DIEGO and ST. GALLEN, Switzerlan...